AbbVie vs Thermo Fisher Scientific at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | ABBV | TMO |
|---|---|---|
| Market cap | $471.46B | $233.04B |
| Price | $265.79 | $628.15 |
| P/E ratio (TTM) | 95.29 | 32.4 |
| P/B ratio (MRQ) | 0 | 4.09 |
| P/S ratio (TTM) | 6.58 | 4.9 |
| Revenue growth (1Y) | 8.57% | 3.91% |
| Return on equity (TTM) | -129.24% | 12.61% |
| Return on invested capital (TTM) | 21.13% | 8.06% |
| Gross margin (TTM) | 73.70% | 40.37% |
| Net margin (TTM) | 5.79% | 15.06% |
| Dividend yield (TTM) | 2.60% | 0.30% |
How they differ
AbbVie is the larger company at $471.46B versus $233.04B — about 2.0x the size.
On trailing earnings, Thermo Fisher Scientific is the cheaper of the two at 32.4 against 95.29 for AbbVie.
On sales, Thermo Fisher Scientific is the cheaper of the two at 4.9 against 6.58 for AbbVie.
AbbVie leads on revenue growth over the past year, 8.57% against 3.91%.
AbbVie leads on return on invested capital, 21.13% against 8.06%.
AbbVie leads on gross margin, 73.70% against 40.37%.
AbbVie offers the higher yield at 2.60% against 0.30%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving AbbVie or Thermo Fisher Scientific.